• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sunovion, Novartis ink licensing deal for inhaled COPD drugs

December 22, 2016 By Sarah Faulkner

Sunovion, Novartis ink licensing deal for inhaled COPD drugsNovartis (NYSE:NVS) said today that it out-licensed its U.S. commercial rights for 3 chronic obstructive pulmonary disease drugs to Sunovion Pharmaceuticals. Novartis will commercialize the Utibron Neohaler, Seebri Neohaler, and Arcapta Neohaler inhalation powders outside of the U.S.

The Switzerland-based company will manufacture the inhaled powders for Sunovion, according to the agreement.

“Given the evolving market dynamics, we believe these products will have the greatest impact in the US when commercialized by a company with an established presence in the COPD field,” Novartis president Fabrice Chouraqui said in prepared remarks. “Novartis will continue to focus on areas in the US where we have strong capabilities and leadership, and can bring the greatest value to physicians and patients.”

In November, the company reported that is was backing off a 2016 start date to test is autofocusing contact lens in clinical trials, but it told Reuters that the product is “progressing steadily”. Novartis and Google (NSDQ:GOOGL). inked a partnership 2 years ago to develop an autofocusing lens for people with presbyopia and a lens that can measure blood glucose levels in diabetes patients.

CEO Joe Jimenez said in 2014 that he hoped the lens would be on the market in 5 years and last year he said his company’s Alcon eye care unit was on track to begin clinical trials in 2016.

Filed Under: Distribution, Featured, Respiratory, Wall Street Beat Tagged With: Google, Novartis, Sunovion Pharmaceuticals

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS